September 21, 2025, marked the 32nd World Alzheimer’s Day. Alzheimer’s disease (AD) is the primary cause of dementia. Often ...

Our approach to treating schizophrenia has changed little for more than half a century. But a shift may be underway, emphasizing novel approaches to the disease and its underlying pathology. This ...

Department of Neurobiology, University of Massachusetts Chan Medical School, Worcester, United States Program in Neuroscience, University of Massachusetts Chan Medical School, Worcester, United States ...

Many people, including scientists and philosophers, assume that self-consciousness originates solely in the brain. This is not merely a philosophical question; modern biotech companies are exploring ...

A comprehensive MCP server that bridges the gap between LLMs and diagram creation through three powerful, independent tools: intelligent format selection, format-specific instruction generation, and ...

If you or someone you love has been diagnosed with schizophrenia, you probably know how difficult it can be to find a treatment that truly works—and one that doesn't cause frustrating or even painful ...

- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive treatment ...

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would ...